(Q44113644)

English

TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome

scientific article published on 17 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

0 references

author name string

Miriam L Hoven-Gondrie

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Esther Bastiaannet

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Robert J van Ginkel

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Albert J H Suurmeijer

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Harald J Hoekstra

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

17 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Journal of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

648-655

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Chemotherapy of Sarcomas of the Limbs by Regional Perfusion

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Current uses of isolated limb perfusion in the clinic and a model system for new strategies

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

TNF dose reduction in isolated limb perfusion.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Reproducibility of a histopathologic grading system for adult soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FJSO.21885

21 January 2018

Identifiers

10.1002/JSO.21885

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44113644&oldid=2106715555"